Paul Keel’s Post

Let us know if you want to learn more about #TULSAPRO!

It's a hard life, but I need to go to Barcelona and speak to the International payer community...Phia does U.S. travel insurance cost-containment and repricing differently than all other companies in International space by leveraging new consumer protection laws in the U.S resulting in better savings at lower claims costs (both net claim costs and repricing fees). Phia uses the same processes for fortune 500 companies in the U.S. Although it seems "different" from an International perspective, our processes are a common best practice in the U.S.  Hope to see you there! #ITICGlobal

It will be exiting to follow the work of Martin Jakobsson and his team at TÜV SÜD, with Their newly established role as the first Danish MDR Notified Body is a significant milestone for Denmark’s life-science ecosystem.. The absence of a notified body in Denmark has been a major roadblock, hindering the flourishing of our dynamic medtech scene and overall value creation. Start-ups and small to medium enterprises (SMEs) have felt the impact. Historically, this situation has made Denmark and the EU a less attractive market for life science, prompting companies to explore other countries and geographies. At Contura International A/S , we’ve witnessed this firsthand. Life science contributes to over 20% of Danish exports, but the rigide 2017 MDR (Medical Device Regulation) and IVDR (In Vitro Diagnostic Regulation) regulations in the EU have adversely affected growth rates and the number of patents filed according to Medicoindustrien. Calling for a more flexible and pragmatic approach to fortify our ecosystem With TÜV SÜD’s expertise and commitment, we’re optimistic that this new Notified Body will pave the way for innovative medical devices to swiftly enter the European market. Let’s strengthen our life-science landscape and foster more groundbreaking advancements.

🔬 𝑫𝒂𝒚 𝟏 𝒐𝒇 𝑨𝒅𝒗𝒂𝒏𝒄𝒆𝒅 𝑻𝒉𝒆𝒓𝒂𝒑𝒊𝒆𝒔 💉 I'm thrilled to be representing Personalize My Medicine at Advanced Therapies today! We're diving deep into the exciting world of cell and gene therapy, exploring its potential for various diseases like brain disorders, rare respiratory disease, Parkinson's disease, etc. The discussions around gene editing, CRISPR/Cas9, gene silencing (GEIS), and viral vector delivery have been incredibly insightful. These innovative approaches hold immense promise for personalised medicine, offering a potential cure for previously untreatable conditions. I'm energised by the collaborative spirit to overcome challenges and make these therapies accessible for patients. Stay tuned for more updates on Personalize My Medicine's role in advancing this revolutionary field! #cellandgenetherapy #personalizedmedicine #PersonalizeMyMedicine #geneediting #GEIS #viralvectors #braindisease #rarespiratorydisease #ParkinsonsDisease Advanced Therapies Congress

Come by and learn how osmolarity and corneal health go hand in hand.

#everfit Wednesday Wellness - I love talking to groups about ‘expansive wellness’. A massive part of being well is being curious about your purpose. Ikigai (the Japanese concept of finding purpose and fulfillment in life) can help with this. This ancient philosophy emphasizes the intersection of what you love, what you're good at, what the world needs, and what you can be paid for. Uncover your reason for being and live a more meaningful life #ikigai #purpose #fulfillment #expansivewellness Click below ⬇️ for resources on how to improve wellbeing & to get in contact for physio/coaching https://lnkd.in/gb8cam7X

Day 2 at DIA Europe 2024 is off to a flying start. Be sure to call in and say hello to the G&L team. Find us at Booth H1 and discover how our services and solutions can help solve your healthcare challenges. Find out more: https://lnkd.in/dX_9VJPw #HealthcareAdvisors #RegulatoryAffairs #ClinicalDevelopment #QualityAssurance

Health-tech from Slovakia 🧑⚕️🇸🇰 Together with Pavol Cekan's MultiplexDX, Michaela Šišková's DNA ERA and others, Forbes Slovensko selected Powerful Medical as one of the most perspective health-tech companies from Slovakia 🙌

Are you heading to SCOPE this year? Are you interested in understanding site burden, and how to think about it in the context of your trial delivery? If so, let’s connect! Eduardas Valaitis will be discussing how to explore site burden as part of your protocol complexity scoring, with some eye opening insights from our most recent site survey, and I will be womaning the #PwC booth (#1201). If you work at or with sites and are rolling your eyes reading this post, let’s chat! We want to hear your opinion, and talk about what resonates with you or what we got wrong! See you in a few weeks!

Snapshot from our 2nd General Assembly in Salzburg, Austria! InnoSer is a proud partner for the HEAL EU Project, which focuses on iPSC-cardiomyocyte aggregate manufacturing technologies for #AllogenicCellTherapy to the heart. As part of evaluation of iPSC-derived cell therapy, InnoSer supports the development of HEAL iPSC-derived cardiomyocyte aggregates by performing #InVivoBiodistribution and #Tumorigenicity studies. InnoSer's team continuously supports industry innovators in their journey toward the approval and the subsequent use in the clinic. For novel therapy types such as ATMPs, rigorous preclinical research is the key to success in clinical trials. For example, our team has extensive experience in beta cell replacement therapy testing including cellular encapsulation in microcapsules and macrodevices or islet kidney capsule transplantation. In the setting of #MyocardialInfarction (MI), our permanent LAD ligation MI model is a highly relevant preclinical model for #ATMPs evaluation as well. To assess tumorigenicity of a novel ATMP, studies in WT and/or mouse models with predisposition to cancer (such as the #p53 KO model) are regularly performed. Get in contact with us to find our more about performing an ATMP evaluation here: https://lnkd.in/eHH4bmZT #Preclinical #CardiometabolicCRO #CardiologyCRO #CRO #DrugDevelopment #AdvancedTherapyMedicinalProducts #Safety #CarcinogenicityStudy #ipscs